<DOC>
	<DOCNO>NCT00723632</DOCNO>
	<brief_summary>The objective study evaluate cost associate peginterferon alfa-2b ( PegIntron ) plus ribavirin ( Rebetol ) treatment chronic hepatitis C Czech Republic . Only cost associated rescue medication , concomitant therapy , disease monitoring , medical intervention cost recognize treat institution treatment-related expense include analysis . The study also evaluate correlation hepatitis C virus ( HCV ) therapy-related cost ribavirin dose participant history .</brief_summary>
	<brief_title>Pharmacoeconomic Study Assessing Cost Chronic Hepatitis C Treatment With Peginterferon Alfa-2b ( PegIntron ) Ribavirin ( Rebetol ) Czech Republic ( Study P04588 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants chronic hepatitis C At least 18 year old Eligibility determine base diagnosis medical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>